مواقع التدريسيينجامعة الكوفة
0Publications
0Lectures
0Interests
0News

About

My researches are focused on investigating the pulmonary transport mechanisms and the role that drug transporters play on pulmonary drug disposition. Furthermore, I am interested in investigating the role of drug transporters such as multidrug resistance associated protein 1 (MRP1), organic cation transporter novel 1 (OCTN1) and breast cancer resistance protein (BCRP) in the pathogenesis of lung diseases such as chronic obstructive pulmonary disease (COPD), asthma and lung fibrosis and the possible interaction of these transporters with inhaled drugs used for treatment of COPD and asthm.

Research Interests

1

Publications

8
2021

In vitro and ex vivo models in inhalation biopharmaceutical research — advances, challenges and future perspectives

AuthorsMohammed Ali Selo, Johannes A.Sakea1Kwang-JinKimcdefgCarstenEhrhardt
JournalAdvanced Drug Delivery Reviews
Abstract

Oral inhalation results in pulmonary drug targeting and thereby reduces systemic side effects, making it the preferred means of drug delivery for the treatment of respiratory disorders such as asthma, chronic obstructive pulmonary disease or cystic fibrosis. In addition, the high alveolar surface area, relatively low enzymatic activity and rich blood supply of the distal airspaces offer a promising pathway to the systemic circulation. This is particularly advantageous when a rapid onset of pharmacological action is desired or when the drug is suffering from stability issues or poor biopharmaceutical performance following oral administration. Several cell and tissue-based in vitro and ex vivo models have been developed over the years, with the intention to realistically mimic pulmonary biological barriers. It is the aim of this review to critically discuss the available models regarding their advantages and limitations and to elaborate further which biopharmaceutical questions can and cannot be answered using the existing models.

2020

Organic Cation Transporters in the Lung—Current and Emerging (Patho)Physiological and Pharmacological Concepts

AuthorsMohammed Ali Selo, Johannes A. Sake,Carsten Ehrhardt and Johanna J. Salomon *
JournalInternational Journal of Molecular Sciences
Abstract

Organic cation transporters (OCT) 1, 2 and 3 and novel organic cation transporters (OCTN) 1 and 2 of the solute carrier 22 (SLC22) family are involved in the cellular transport of endogenous compounds such as neurotransmitters, l-carnitine and ergothioneine. OCT/Ns have also been implicated in the transport of xenobiotics across various biological barriers, for example biguanides and histamine receptor antagonists. In addition, several drugs used in the treatment of respiratory disorders are cations at physiological pH and potential substrates of OCT/Ns. OCT/Ns may also be associated with the development of chronic lung diseases such as allergic asthma and chronic obstructive pulmonary disease (COPD) and, thus, are possible new drug targets. As part of the Special Issue “Physiology, Biochemistry and Pharmacology of Transporters for Organic Cations”, this review provides an overview of recent findings on the (patho)physiological and pharmacological functions of organic cation transporters in the lung.

2020

Tobacco Smoke and Inhaled Drugs Alter Expression and Activity of Multidrug Resistance-Associated Protein-1 (MRP1) in Human Distal Lung Epithelial Cells in vitro

AuthorsMohammed Ali Selo, Anne-Sophie Delmas, Lisa Springer, Viktoria Zoufal, Johannes A Sake, Caoimhe G Clerkin, Hanno Huwer, Nicole Schneider-Daum, Claus-Michael Lehr, Sabrina Nickel, Oliver Langer, Carsten Ehrhardt
JournalFrontiers in Bioengineering and Biotechnology
Abstract

Multidrug resistance-associated protein-1 (MRP1/ABCC1) is highly expressed in human lung tissues. Recent studies suggest that it significantly affects the pulmonary disposition of its substrates, both after pulmonary and systemic administration. To better understand the molecular mechanisms involved, we studied the expression, subcellular localization and activity of MRP1 in freshly isolated human alveolar epithelial type 2 (AT2) and type 1-like (AT1-like) cells in primary culture, and in the NCI-H441 cell line. Moreover, the effect of cigarette smoke extract (CSE) and a series of inhaled drugs on MRP1 abundance and activity was investigated in vitro. MRP1 expression levels were measured by q-PCR and immunoblot in AT2 and AT1-like cells from different donors and in several passages of the NCI-H441 cell line. The subcellular localization of the transporter was studied by confocal laser scanning microscopy and cell surface protein biotinylation. MRP1 activity was assessed by bidirectional transport and efflux experiments using the MRP1 substrate, 5(6)-carboxyfluorescein [CF; formed intracellularly from 5(6)-carboxyfluorescein-diacetate (CFDA)] in AT1-like and NCI-H441

2019

Photodynamic therapy of ovarian carcinoma cells with curcumin-loaded biodegradable polymeric nanoparticles

AuthorsLili Duse, Michael Rene Agel, Shashank Reddy Pinnapireddy, Jens Schäfer, Mohammed Ali Selo, Carsten Ehrhardt, Udo Bakowsky
JournalPharmaceutics
Abstract

Accumulation of photosensitisers in photodynamic therapy in healthy tissues is often the cause of unwanted side effects. Using nanoparticles, improved bioavailability and site-specific drug uptake can be achieved. In this study, curcumin, a natural product with anticancer properties, albeit with poor aqueous solubility, was encapsulated in biodegradable polymeric poly(lactic-co-glycolic acid) (PLGA) nanoparticles (CUR-NP). Dynamic light scattering, laser Doppler anemometry and atomic force microscopy were used to characterise the formulations. Using haemolysis, serum stability and activated partial thromboplastin time tests, the biocompatibility of CUR-NP was assessed. Particle uptake and accumulation were determined by confocal laser scanning microscopy. Therapeutic efficacy of the formulation was tested in SK-OV-3 human ovarian adenocarcinoma cells post low level LED irradiation by determining the generation of reactive oxygen species and cytotoxicity. Pharmacologic inhibitors of cellular uptake pathways were used to identify the particle uptake mechanism. CUR-NP exhibited better physicochemical properties such as stability in the presence of light and improved serum stability compared to free curcumin. In addition, the novel nanoformulation facilitated the use of higher amounts of curcumin and showed strong apoptotic effects on tumour cells.

2019

OCTN2-Mediated Acetyl-l-Carnitine Transport in Human Pulmonary Epithelial Cells In Vitro

Authors Johanna J Salomon,, Julia C Gausterer, Mohammed Ali Selo, Ken-ichi Hosoya, Hanno Huwer, Nicole Schneider-Daum, Claus-Michael Lehr, Carsten Ehrhardt
JournalPharmaceutics
Abstract

The carnitine transporter OCTN2 is associated with asthma and other inflammatory diseases. The aims of this work were (i) to determine carnitine uptake into freshly isolated human alveolar type I (ATI)-like epithelial cells in primary culture, (ii) to compare the kinetics of carnitine uptake between respiratory epithelial in vitro cell models, and (iii) to establish whether any cell line was a suitable model for studies of carnitine transport at the air-blood barrier. Levels of time-dependent [3H]-acetyl-l-carnitine uptake were similar in ATI-like, NCl-H441, and Calu-3 epithelial cells, whereas uptake into A549 cells was ~5 times higher. Uptake inhibition was more pronounced by OCTN2 modulators, such as l-Carnitine and verapamil, in ATI-like primary epithelial cells compared to NCl-H441 and Calu-3 epithelial cells. Our findings suggest that OCTN2 is involved in the cellular uptake of acetyl-l-carnitine at the alveolar epithelium and that none of the tested cell lines are optimal surrogates for primary cells.

2018

Investigation of supersaturation and in vitro permeation of the poorly water soluble drug ezetimibe.

AuthorsAmani Alhayali, Mohammed Ali Selo, Carsten Ehrhardt, Sitaram Velaga
JournalEuropean Journal of Pharmaceutical Sciences
Abstract

The interplay between supersaturation, precipitation and permeation characteristics of the poorly water-soluble drug ezetimibe (EZ) was investigated. Supersaturation and precipitation characteristics of EZ in the presence of Caco-2 cells were compared to those in a cell-free environment. The effect of the water-soluble polymer polyvinyl pyrrolidone (PVP-K30) on the supersaturation, precipitation and transport of EZ was also investigated and the amount of drug taken up by Caco-2 cells was quantified. A one-compartment setup without Caco-2 cells (i.e. in the wells of cell-culture plates) was used to mimic a non-sink in vitro dissolution chamber. The two-compartment Caco-2 cell monolayer setup (with apical and basolateral compartments) was used to investigate how the absorption of EZ affects supersaturation. EZ in varying degrees of supersaturation (DS; 10, 20, 30 and 40) was introduced into the one-compartment setup or the apical chamber of the two-compartment setup. Samples were collected at specific times to determine supersaturation, precipitation and permeation. At the end of the study, Caco-2 cells were lysed and the intracellular amount of EZ was quantified. In the one-compartment setup, a high DS was associated with rapid precipitation. Supersaturation was maintained for longer time periods and precipitation was lower in the presence of Caco-2 cells. There were no significant differences in the absorption rate of the drug, even at high concentrations on the apical side. Permeability coefficients for all supersaturated solutions (i.e. DS 10-40) were significantly (p < 0.05) different from those when EZ was present in crystalline form. Both concentrations of PVP-K30 (i.e. 0.05% and 0.1% w/v) improved solubility and supersaturation of EZ when added to the apical side, however, the increase in absorption at the higher concentration was not proportional. The amount of intracellular EZ increased with increasing DS in the apical side, until the saturation limit was reached in the cells (i.e. at DS 30 and higher). This study demonstrated that precipitation of EZ could be overestimated when supersaturation was investigated without the implementation of an absorption compartment in vitro, both in the absence and in the presence of polymer.

2017

Expression and Activity of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Distal Lung Epithelial Cells In Vitro.

AuthorsSabrina Nickel and Mohammed Ali Selo contributed equally to this work, & Mohammed Ali Selo & Juliane Fallack & Caoimhe G. Clerki & Hanno Huwer & Nicole Schneider-Daum & Claus-Michael Lehr & Carsten Ehrhardt
Journal Pharmaceutical Researches
Abstract

PURPOSE: Breast cancer resistance protein (BCRP/ABCG2) has previously been identified with high expression levels in human lung. The subcellular localisation and functional activity of the transporter in lung epithelia, however, remains poorly investigated. The aim of this project was to study BCRP expression and activity in freshly isolated human alveolar epithelial type 2 (AT2) and type 1-like (AT1-like) cells in primary culture, and to compare these findings with data obtained from the NCI-H441 cell line. METHODS: BCRP expression levels in AT2 and AT1-like cells and in different passages of NCI-H441 cells were determined using q-PCR and immunoblot. Transporter localisation was confirmed by confocal laser scanning microscopy. Efflux and transport studies using the BCRP substrate BODIPY FL prazosin and the inhibitor Ko143 were carried out to assess BCRP activity in the different cell models. RESULTS: BCRP expression decreased during transdifferentiation from AT2 to AT1-like phenotype. Culturing NCI-H441 cells at an air-liquid interface or submersed did not change BCRP abundance, however, BCRP levels increased with passage number. BCRP was localised to the apical membrane and cytosol in NCI-H441 cells. In primary cells, the protein was found predominantly in the nucleus. Functional studies were consistent with expression data. CONCLUSIONS: BCRP is differently expressed in AT2 and AT1-like cells with lower abundance and activity in the latter ones. Nuclear BCRP might play a transcriptional role in distal lung epithelium. In NCI-H441 cells, BCRP is expressed in apical cell membranes and its activity is consistent with the localisation pattern.

2016

Transport mechanisms at the pulmonary mucosa: implications for drug delivery.

AuthorsSabrina Nickel,, Caoimhe G. Clerkin, Mohammed Ali Selo & Carsten Ehrhardt
JournalExpert Opinion on Drug Delivery
Abstract

INTRODUCTION: Over the past years, a significant number of papers have substantiated earlier findings proposing a role for drug transporter proteins in pulmonary drug disposition. Whilst the majority of reports present data from in vitro models, a growing number of publications advance the field by introducing sophisticated ex vivo and in vivo techniques. In a few cases, evidence from clinical studies in human volunteers is complementing the picture. AREAS COVERED: In this review, recent advances in pulmonary drug transporter research are critically evaluated. Transporter expression data in tissues and cell-based in vitro models is summarized and information on transport activity assessed. Novel techniques allowing for better quantification of transporter-related effects following pulmonary delivery are also described. EXPERT OPINION: Different tissue and cell populations of the lung have distinct transporter expression patterns. Whether these patterns are affected by disease, gender and smoking habits requires further clarification. Transporters have been found to have an impact on drug absorption processes, at least in vitro. Recent ex vivo experiments using isolated, perfused lung models, however, suggest that mainly efflux pumps have significant effects on absorption into the pulmonary circulation. Whether these rodent-based ex vivo models predict the human situation is basis for further research.

Lectures

10

Epilepsy

Applied Therapeutics II

Status Epilepticus

Applied Therapeutics II

Parkinson's disease

Applied Therapeutics II

Multiple Sclerosis

Applied Therapeutics II

Hypertension

Applied Therapeutics II

Angina Pectoris

Applied Therapeutics II

Heart Failure

Hospital Training

Cardiac Arrhythmia

Hospital Training

Hypertension

Hospital Training

Angina Pectoris

Hospital Training

News & Announcements

1
News 2019-01-22

I am honoured with the American Thoracic Society (ATS) Assembly on Respiratory Cell and Molecular Biology Jo Rae Wright Early Investigator Award at the ATS International Conference in Washington DC in May 2017

I have received the ATS Assembly on Respiratory Cell and Molecular Biology Jo Rae Wright Early Investigator Award at the ATS International Conference in Washington, DC. “This award was created in memory of Dr Jo Rae Wright, a brilliant researcher, leader and mentor who made selfless contributions to her trainees and colleagues. The award is given in recognition of outstanding scientific achievement by a young investigator with the goal to identify the rising stars of RCMB and encourage their scientific careers.” Dr. Mohammed Ali Selo, who was reading toward his PhD under the mentorship of Dr. Carsten Ehrhardt, was selected for the award with his work titled: Ergothioneine Induces Antioxidant Enzymes in Human Lung Epithelial Cells In-Vitro. Dr. Mohammed Ali’s PhD project, which is supported by the Flight Attendant Medical Research Institute (FAMRI) and the Iraqi Ministry of Higher Education and Scientific Research (MOHESR), investigates the role of ergothioneine and its physiological transporter OCTN1 in second-hand smoke-related chronic obstructive pulmonary disease (COPD). For more details, please visit the website below of the school of pharmacy / Trinity college Dublin / Ireland https://pharmacy.tcd.ie/news/mohammed-ali-selo-award-2017.php

View details